安罗替尼联合化疗和新辅助治疗激素受体阳性 HER-2 阴性乳腺癌 (ACNTBC)

实验性的：安罗替尼

安罗替尼是一种口服多靶点酪氨酸激酶抑制剂 (TKI)，可强烈抑制 VEGFR、PDGFR、FGFR 和 c-kit。 安罗替尼（12 mg qd，d1-14；每个周期 21 天；总共 5 个周期）联合 TAC×6 个周期。

药品：安罗替尼

安罗替尼（12 mg qd，d1-14；每个周期 21 天；共 5 个周期）联合 TAC×6 个周期：白蛋白结合紫杉醇（200mg/m2，1d Q3W）+吡柔比星（50mg/m2，1d Q3W）+环磷酰胺（ 500mg/m2, 1d Q3W);

其他名称：

• 交战委员会

Pathological Complete Response (pCR) Rate

Pathological complete response (pCR),which was also identified as total pCR (tpCR), was defined as the absence of invasive cancer in breast and no metastasis to regional lymph nodes (ypT0/is ypN0) in the surgical specimen after completion of neoadjuvant therapy, corresponding to Residual Cancer Burden (RCB) score of 0. Pathological response was evaluated by an independent pathologist blinded to treatment assignment on the resected breast specimen and axillary lymph nodes using H&E staining. The RCB grading system was used as the primary method to quantify residual disease. RCB I indicates minimal residual disease. RCB II indicates moderate residual disease. RCB III indicates extensive residual disease (worst outcome). Lower RCB scores represent better pathological response and are associated with improved long-term survival outcomes. tpCR was considered the most stringent and clinically meaningful endpoint for neoadjuvant studies, representing complete eradication of invasive tumor.

RCB 0/I Rate

The outcome measure is defined as the proportion of participants who achieve a Residual Cancer Burden (RCB) class of 0 or I following neoadjuvant therapy and surgical resection. RCB score is calculated using the standardized RCB calculator. Pathological evaluation is performed on surgical specimens according to institutional or central laboratory guidelines.

RCB 0: Pathologic complete response (pCR), defined as no residual invasive carcinoma in the breast primary tumor and ipsilateral axillary lymph nodes (in situ carcinoma allowed).

RCB I: Minimal residual tumor burden, indicating extensive tumor regression with only minor residual disease.

Number of Participants With Treatment-Related Adverse Events (TRAEs)

For safety evaluation, the severity grade (according to National Cancer Institute Common Terminology Criteria for Adverse Events, v 5.0) and the relationship to study treatment of AEs were assessed by physical examination and laboratory tests before and after every cycle, during follow-up visits, and upon indication by symptoms.

EFS

EFS(Event-free survival)

bpCR Rate

The outcome measure is defined as the proportion of participants who achieve breast pathologic complete response (bpCR) following neoadjuvant therapy and surgical resection.

bpCR is defined as no residual invasive carcinoma in the breast primary tumor (residual ductal carcinoma in situ [DCIS] is allowed), regardless of axillary lymph node status.

apCR Rate

The outcome measure is defined as the proportion of participants who achieve axillary pathologic complete response (apCR) following neoadjuvant therapy and surgical resection.

apCR is defined as no residual invasive carcinoma in the ipsilateral axillary lymph nodes, regardless of breast primary tumor status.